İLKNUR ÇALIK, MUHAMMET ÇALIK, Hanifi İbrahim ÖZERCAN, Adile Ferda DAĞLI, Gökhan ARTAŞ, Gülistan TÜRKEN, Burcu SARIKAYA

Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer

Objective: Since colorectal cancers (CRC) are tumors with heterogeneous biological behavior, prediction of theirprognosis remains challenging. Caudal-related homeobox gene 2 (CDX2), which has important roles in the developmentand maintenance of intestines, is thought to have tumor suppressing effect on CRCs. The aim of this study was toinvestigate the prognostic significance of decreased-CDX2 expression.Method: This retrospective study included 224 patients diagnosed with CRC between 2009 and 2014. Paraffinized blocksof these patients were stained with CDX2 immunohistochemically and evaluated semiquantitatively.Results: Only 35 (15.6%) of 224 patients had low-CDX2 expression. Decrease in CDX2 expression was closely associatedwith classical prognostic parameters such as histopathologic type, histologic grade, lymph node metastasis, distantmetastasis, and TNM stage. Patients with decreased-CDX2 expression had more lymph node metastasis (p=0.013) andadvanced TNM stage (p=0.004) than those without decreased-expression. The mean survival was 53.0±0.89 months. Coxregression analysis showed that decreased-CDX2 expression was significantly related with overall survival (Univariateanalysis; hazard ratio: 0.09, 95% confidence interval: 0.05-0.16; p

Azalmış CDX2 Ekspresyonu Kolorektal Kanserli Hastaların Prognozunu Olumsuz Yönde Etkiliyor

Amaç: Kolorektal kanserler heterojen biyolojik davranışa sahip tümörler olduğu için prognozlarının önceden belirlenmesi zorlayıcı olmaya devam etmektedir. Bağırsakların gelişiminde ve devamlılığında önemli görevleri olan caudal-related homeobox gene 2 (CDX2)'nin CRC'lerde tümör baskılayıcı etkisi olduğu da düşünülmektedir. Bu çalışmada CDX2 ekspresyonundaki azalmanın prognostik öneminin araştırılması amaçlandı. Yöntemler: Bu retrospektif çalışmaya 2009-2014 yılları arasında CRC tanısı alan 224 hasta dahil edildi. Bu hastalara ait parafinize bloklar immunohistokimyasal olarak CDX2 ile boyanıp semikantitatif olarak değerlendirildi. Bulgular: İki yüz yirmi dört hastanın sadece 35'inde (15.6%) düşük CDX2 ekspresyonu vardı. CDX2 ekspresyonundaki azalma histopatolojik tip, histolojik derece, lenf nodu metastazı, uzak metastaz ve TNM evresi gibi klasik prognostik parametreler ile yakından ilişkiliydi. CDX2 ekspresyonunda azalma olan hastalarda, ekspresyonda azalma olmayanlara göre daha fazla lenf nodu metastazı ve ileri TNM evresi vardı. Ortalama sağkalım 53.0±0.89 ay olarak belirlendi. Cox regresyon analizi, azalmış CDX2 ekspresyonunun genel sağkalım (Tek değişkenli analiz; tehlike oranı: 0.09, %95 güven aralığı: 0.05-0.16; p

PDF

___

1. Haddad FG, Eid R, Kourie HR, Barouky E, Ghosn M. Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. Future Oncol 2018; 14: 2097-102.

2. Akdeniz N, Kaplan MA, Küçüköner M, et al. Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Med J 2019; 46: 247-53.

3. Slik K, Turkki R, Carpén O, et al. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma. Am J Surg Pathol 2019; 43: 1473-82.

4. Xiong Y, You W, Hou M, et al. Nomogram Integrating Genomics with Clinicopathologic Features Improves Prognosis Prediction for Colorectal Cancer. Mol Cancer Res 2018; 16: 1373-84.

5. Shigematsu Y, Inamura K, Yamamoto N, et al. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer 2018; 18: 980.

6. Shigematsu Y, Inamura K, Mise Y, et al. CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan. Oncotarget 2018; 9: 17056-65.

7. Bae JM, Lee TH, Cho NY, Kim TY, Kang GH. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol 2015; 21: 1457-67.

8. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004; 17: 1392-99.

9. Hryniuk A, Grainger S, Savory JG, Lohnes D. Cdx1 and Cdx2 function as tumor suppressors. J Biol Chem 2014; 289: 33343-54.

10. Matsuda M, Sentani K, Noguchi T, et al. Immunohistochemical analysis of colorectal cancer with gastric phenotype: claudin-18 is associated with poor prognosis. Pathol Int 2010; 60: 673-80.

11. Xu W, Zhu Y, Shen W, et al. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer. J Int Med Res 2019; 47: 1829-42.

12. Hong KD, Lee D, Lee Y, Lee SI, Moon HY. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg 2013; 79: 353-60.

13. Hari DM, Leung AM, Lee JH, et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg 2013; 217: 181-90.

14. Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 2016; 374: 211–22.

15. Olsen J, Espersen ML, Jess P, Kirkeby LT, Troelsen JT. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. Surg Oncol 2014; 23: 167- 76.

16. Hansen TF, Kjaer-Frifeldt S, Eriksen AC, et al. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. Br J Cancer 2018; 119: 1367-73.

17. Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol 2008; 21: 1403-12.

18. Tóth C, Sükösd F, Valicsek E, et al. Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. Oncol Lett 2018; 15: 3586-93.

19. Misiakos EP, Karidis NP and Kouraklis G: Current treatment for colorectal liver metastases. World J Gastroenterol 2011; 17: 4067-75.

20. Baba Y, Nosho K, Shima K, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 2009; 15: 4665-73.

21. Dawson H, Galván JA, Helbling M, et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer 2014; 134: 2342-51.

22. Dawson H, Koelzer VH, Lukesch AC, et al. Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch RepairDeficiency in Colorectal Cancer. Front Oncol 2013; 3: 265.